Andrew M Kidger
Overview
Explore the profile of Andrew M Kidger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balmanno K, Kidger A, Byrne D, Sale M, Nassman N, Eyers P, et al.
Biochem J
. 2023 Apr;
480(9):587-605.
PMID: 37018014
Innate or acquired resistance to small molecule BRAF or MEK1/2 inhibitors (BRAFi or MEKi) typically arises through mechanisms that sustain or reinstate ERK1/2 activation. This has led to the development...
2.
Kidger A, Saville M, Rushworth L, Davidson J, Stellzig J, Ono M, et al.
Oncogene
. 2022 Apr;
41(20):2811-2823.
PMID: 35418690
The cytoplasmic phosphatase DUSP6 and its nuclear counterpart DUSP5 are negative regulators of RAS/ERK signalling. Here we use deletion of either Dusp5 or Dusp6 to explore the roles of these...
3.
Ferguson B, Wennersten S, Demos-Davies K, Rubino M, Robinson E, Cavasin M, et al.
Am J Physiol Heart Circ Physiol
. 2021 Jun;
321(2):H382-H389.
PMID: 34142888
Pulmonary hypertension (PH) is associated with structural remodeling of pulmonary arteries (PAs) because of excessive proliferation of fibroblasts, endothelial cells, and smooth muscle cells (SMCs). The peptide hormone angiotensin II...
4.
Lochhead P, Tucker J, Tatum N, Wang J, Oxley D, Kidger A, et al.
Nat Commun
. 2020 Mar;
11(1):1383.
PMID: 32170057
The dual protein kinase-transcription factor, ERK5, is an emerging drug target in cancer and inflammation, and small-molecule ERK5 kinase inhibitors have been developed. However, selective ERK5 kinase inhibitors fail to...
5.
Kidger A, Munck J, Saini H, Balmanno K, Minihane E, Courtin A, et al.
Mol Cancer Ther
. 2019 Nov;
19(2):525-539.
PMID: 31748345
The RAS-regulated RAF-MEK1/2-ERK1/2 signaling pathway is frequently deregulated in cancer due to activating mutations of growth factor receptors, RAS or BRAF. Both RAF and MEK1/2 inhibitors are clinically approved and...
6.
Odle R, Walker S, Oxley D, Kidger A, Balmanno K, Gilley R, et al.
Mol Cell
. 2019 Nov;
77(2):228-240.e7.
PMID: 31733992
Since nuclear envelope breakdown occurs during mitosis in metazoan cells, it has been proposed that macroautophagy must be inhibited to maintain genome integrity. However, repression of macroautophagy during mitosis remains...
7.
Seternes O, Kidger A, Keyse S
Biochim Biophys Acta Mol Cell Res
. 2018 Nov;
1866(1):124-143.
PMID: 30401534
It is well established that a family of dual-specificity MAP kinase phosphatases (MKPs) play key roles in the regulated dephosphorylation and inactivation of MAP kinase isoforms in mammalian cells and...
8.
Kidger A, Sipthorp J, Cook S
Pharmacol Ther
. 2018 Feb;
187:45-60.
PMID: 29454854
The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is de-regulated in a variety of cancers due to mutations in receptor tyrosine kinases (RTKs), negative regulators of RAS (such as NF1) and core pathway...
9.
Kidger A, Cook S
FEBS J
. 2018 Jan;
285(1):42-45.
PMID: 29314599
The protein kinases ERK1/2 and RSK associate in unstimulated cells but must separate to target other substrates. In this issue, Gógl et al. show that phosphorylation of RSK by active...
10.
Sipthorp J, Lebraud H, Gilley R, Kidger A, Okkenhaug H, Saba-El-Leil M, et al.
Bioconjug Chem
. 2017 Apr;
28(6):1677-1683.
PMID: 28449575
The RAS-RAF-MEK-ERK pathway has been intensively studied in oncology, with RAS known to be mutated in ∼30% of all human cancers. The recent emergence of ERK1/2 inhibitors and their ongoing...